RC
BBIO icon

Rangeley Capital’s BridgeBio Pharma BBIO Stock Holding History

Rangeley Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,000
Closed -$473K – 75
2025
Q1 		$449K Hold
13,000
– – 0.48% 39
2024
Q4 		$357K Buy
+13,000
New +$336K 0.32% 50

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rangeley Capital's BBIO Position: Q2 2025 in Review

Rangeley Capital sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 13,000 shares — an estimated $473K sold.

Rangeley Capital first reported a position in BBIO in Q4 2024 and held it in 2 quarters. The position peaked at $449K in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

  • Rangeley Capital reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
  • Rangeley Capital sold 13,000 BridgeBio Pharma shares in Q2 2025, an estimated $473K.
  • Rangeley Capital first reported a position in BridgeBio Pharma in Q4 2024 and held it in 2 quarters.
  • Rangeley Capital's BridgeBio Pharma position peaked at $449K in Q1 2025.
  • 359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.